Senolytic flavonoid supplement

Fisetin

In a 2022 crossover study of 15 healthy volunteers, fisetin's plasma half-life was 1.14 hours for unformulated fisetin; the app lists 4 hours.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Fisetin after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.

Drawn from the half-life in the app's model, ~4 h. The model's figures

Fisetin is a flavonoid found naturally in plants, fruits and vegetables, and it has been studied as a senotherapeutic, a compound aimed at senescent cells.2 Yousefzadeh and colleagues at the Mayo Clinic Kogod Center on Aging, writing in EBioMedicine in 2018, screened a panel of flavonoids and reported "Of the 10 flavonoids tested, fisetin was the most potent senolytic".3 The app grades the evidence for fisetin as emerging, lists it as a senolytic, and gives an oral route and a typical dose of 100 to 500 mg/day. The human reports described below are one pharmacokinetic study, placebo-controlled trials in colorectal cancer, stroke, Gulf War illness and knee osteoarthritis, a pilot in healthy adults, and registry entries.

2

How it works

Yousefzadeh and colleagues tested fisetin for senolytic activity in senescent mouse and human fibroblasts, in progeroid and aged mice, and in human adipose tissue explants.3 They describe the pattern in mice as "consistent with a hit-and-run senolytic mechanism".3 They also leave other explanations open, writing that "it is also possible that the extension of healthspan is due to mechanisms in addition to the reduction in senescence".3 Human omental fat explants from surgery were treated with 20 μM fisetin for 48 hours in the laboratory, and the paper reports fewer SA-ß-gal positive cells and lower IL-6, IL-8 and MCP-1 expression; this was tissue in a dish, not a trial in people, and the cytokine measurements used 3 biological replicates.3 A later mouse study in UM-HET3 mice, which differed from the 2018 work in strain, dose and schedule, reported: "Neither of the two groups of Fis-treated mice had significantly lower numbers of p16Ink4a-positive cells, compared to age-matched untreated control mice."4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
40%
Typical dose
100–500 mg/day
Route
Oral
Time to peak
~3 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~4 hPlasma half-life of 1.14 h (unformulated fisetin) and 1.51 h (a formulated product, FF-20) in 15 healthy volunteers, with results adjusted for fisetin content; the same study gives 1.18 h and 1.59 h for the metabolite geraldol; Yousefzadeh and colleagues cite "rapid and terminal half-lives of fisetin" of 0.09 and 3.1 h in the discussion of their mouse experiments, in a sentence that does not name the species1,3
Bioavailability40%No absolute bioavailability percentage is reported in the 2022 study, whose authors conclude it "demonstrated the poor bioavailability of fisetin in human subjects"; at 1000 mg unformulated fisetin reached a mean Cmax of 9.97 ng/ml, and plasma fisetin from the formulated product had an AUC 26.9-fold greater1
Time to peak~3 hMean time to maximum plasma concentration of 0.88 h (unformulated fisetin) and 1.24 h (FF-20); geraldol 0.9 h and 1.13 h1
Duration8 hPlasma fisetin was quantifiable up to 2 h after unformulated fisetin and up to 8 h after FF-201

The 2022 study described fisetin as having "high lipophilicity (log P: 3⋅2), poor water solubility (10 μg/ml)".1 Participants were dosed "in a fasted state (≥10 h)", and the study compared formulations, not dosing with and without fat or food.1 The authors report that "Detectable fisetin levels were very low and not quantifiable by UPLC-ESI-MS/MS methods when individuals were supplemented with less than 1000 mg of UF".1

4

Human studies

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Krishnakumar and colleagues, Journal of Nutritional Science 20221Randomised, double-blind, single-dose crossover; financially supported by Akay Natural Ingredients115 healthy volunteers (12 men, 3 women, aged 22–55 years)11000 mg unformulated fisetin or 1000 mg FF-20 (192 mg fisetin), single dose, 10-day washout1Fisetin half-life 1.14 h against 1.51 h; Cmax 9.97 against 238.2 ng/ml; AUC0–12 h 12.67 against 341.4 ng h/ml; two gastrointestinal events (bloating, decreased appetite)1
Wang and colleagues, Clinical and Applied Thrombosis/Hemostasis 20195Double-blind, randomised, placebo-controlled; no financial support declared5192 eligible patients with ischemic stroke given rt-PA: 130 treated 0 to 3 h and 62 treated 3 to 5 h after onset5100 mg fisetin or placebo with rt-PA, then 100 mg daily for 7 days5No difference from placebo in NIHSS scores in the 0 to 3 h group at day 1; lower NIHSS scores with fisetin in the 3 to 5 h group; the day 7 NIHSS distribution followed the same trend as day 1; serum MMP-2, MMP-9 and CRP were reported lower with fisetin than placebo at day 1 and day 7; no fisetin adverse-event counts in the text5
Farsad-Naeimi and colleagues, Food and Function 20186Double-blind, randomised, placebo-controlled; registered at irct.ir; the PubMed record read gives no funding or conflict statement637 colorectal cancer patients undergoing chemotherapy6100 mg fisetin (n = 18) or placebo (n = 19) for seven consecutive weeks6IL-8 and hs-CRP fell in the fisetin group, and MMP-7 values also fell in the fisetin group; against placebo, significant changes were observed only in IL-8; other factors not significantly changed6
Hodgin and colleagues, International Journal of Environmental Research and Public Health 20217Placebo-controlled, pseudo-randomised crossover; Department of Defense funded, no conflict of interest declared721 male veterans with Gulf War illness were analysed across three botanicals; 11 took fisetin, 10 in the primary fisetin analysis71 month placebo, then 200 mg/day, then 800 mg/day, each for 1 month7Symptom severity 41.9 at baseline, 41.0 on placebo, 40.3 on 200 mg/day, 39.5 on 800 mg/day, with no significant effect on overall symptoms, pain or fatigue; one participant stopped the 800 mg/day dose after one week because of worsening nausea and GERD, and one withdrew soon after starting fisetin with a swollen lymph node judged not related to treatment7
Lee and Burns, Alternative Therapies in Health and Medicine 20248Pilot study; all ten participants received fisetin; the PubMed record read gives no funding or conflict statement810 healthy adults over 50 years8500 mg daily for one week per month for six months8Biological age (TruAge test) fell in 4 of 10, rose in 5 and was unchanged in 1; telomere length not statistically changed; no adverse effects noted; the authors write that "taking Fisetin as an anti- aging agent is not recommended until more extensive studies are done"8
Registry entry NCT04210986, Steadman Philippon Research Institute, results posted 20249Phase 1/2 randomised, quadruple-masked, placebo-controlled; sponsor is the research institute with Department of Defense and Office of Naval Research collaborators9Patients with symptomatic knee osteoarthritis; 34 fisetin and 40 placebo participants dosed9100 mg capsules, about 20 mg/kg/day, for 2 days, 28 days off, then 2 more days9At least one adverse event in 28 of 34 on fisetin and 33 of 40 on placebo (odds ratio 0.99, 95% CI 0.25 to 4.02); serious events in 2 and 2; no deaths9
Registry entry NCT04771611, COVFIS-HOME, results posted 202310Phase 2 randomised, double-masked, placebo-controlled; responsible party James L. Kirkland1055 outpatients with COVID-19 and at least one high-risk criterion (29 fisetin, 26 placebo)10About 20 mg/kg/day orally for four days (days 0, 1, 8 and 9); 60 days10Scale score of no limitations in 26 of 27 analysed on fisetin and 22 of 24 on placebo; serious events 0 against 2; no deaths10

Three other fisetin trials are registered without posted results in the entries read: COVID-FISETIN (Mayo Clinic, hospitalised adults with COVID-19, active, not recruiting), AFFIRM (Mayo Clinic, older women, enrolling by invitation) and a Steadman Philippon dosing-equivalence study (completed).11,12,13

Deeper analysis: the human pharmacokinetic study (Krishnakumar and colleagues, 2022)

Four of the six authors, led by Krishnakumar, are affiliated with Akay Natural Ingredients in Cochin, India, and two (Jaja-Chimedza and Swick) with Life Extension in the USA; they reported a single-dose, double-blind crossover study in the Journal of Nutritional Science in 2022.1 They state: "This is the first human pharmacokinetic study of fisetin following a single-dose, comparative, double-blinded, cross-over protocol, supplementing with FF-20 and unformulated fisetin (UF)".1 Fifteen healthy volunteers received 1000 mg of unformulated fisetin or 1000 mg of FF-20, which delivers 192 mg of fisetin, with a 10-day washout between doses.1 The assay measured free (unconjugated) fisetin, and "All results shown were adjusted for the difference in fisetin content".1 Unformulated fisetin reached a mean Cmax of 9.97 ng/ml at 0.88 h and was quantifiable for 2 hours, against 238.2 ng/ml at 1.24 h and 8 hours for FF-20.1 The authors' summary says "No adverse events were reported during the study.", while the results section reports two gastrointestinal events, "one was a bloating sensation and the other one was a decrease in appetite", with the same observations after both products.1 The only limitation the authors name is that "The lack of measurements of fisetin glucuronides and sulphates may be a limitation of the present study".1 The study was "financially supported by Akay Natural Ingredients", which holds the patents on the formulation technology used for FF-20, and the paper states that Life Extension sells FF-20 as Bio-Fisetin.1

Deeper analysis: mouse lifespan studies (Yousefzadeh and colleagues, 2018; Harrison and colleagues, 2024)

Yousefzadeh and colleagues fed wild-type mice "a diet containing 500 ppm fisetin beginning at 85 wks of age" and report "an extension of median as well as maximal lifespan", with n = 8–9 mice per group for lifespan.3 The text of the paper prints no percentage for the mouse lifespan gain; the only percentages near the topic are 55% in yeast and 23% in fruit flies, which the authors cite from earlier work.3 The 2024 report by Harrison and colleagues describes that earlier experiment as a median lifespan of 27 months in controls and 30 months in fisetin-treated mice, with 3 of 8 treated mice outliving all 8 controls.4 The study was funded by National Institutes of Health grants and foundation awards, and the authors J.L.K., T.T., Y.Z., M.X. and T.P. declare "a financial interest related to this research", with senolytic patents held by Mayo Clinic.3 Harrison and colleagues tested fisetin at 600 ppm from 20 months of age in UM-HET3 mice, fed continuously or 3 days on and 11 days off.4 They report that astaxanthin and meclizine extended male lifespan, and that for fisetin and four other agents "None of these increased lifespan significantly at the dose and method of administration tested in either sex".4 The two studies differ in strain, start age, dose and schedule, so the reports do not directly test the same question, and the 2024 report lists authors who are also authors of the 2018 paper, including Kirkland, Tchkonia, Yousefzadeh and Robbins.4,3 The 2024 authors write that their study used "30 × larger numbers of mice compared to the earlier study", that the discrepancy "may reflect the use of different mouse stocks or inter-laboratory variations in husbandry conditions", and that they "were not able to reproducibly detect Fis in the plasma of the treated mice".4 The 2024 report was funded in part by National Institute on Aging grants, with some of the studies at one site also supported by the Glenn Foundation for Medical Research, and its conflict statement notes "Mayo Clinic holds patents on certain senolytic agents. None is currently licensed. TT holds shares from Unity Biotechnology. PDR is the cofounder of Itasca Therapeutics, a virtual startup to develop novel senotherapeutics."; the senescent-cell assays were performed by the Robbins lab.4

Deeper analysis: the Gulf War illness trial (Hodgin and colleagues, 2021)

Hodgin and colleagues at the University of Alabama at Birmingham screened nine botanicals for Gulf War illness; the report covering resveratrol, luteolin and fisetin appeared in the International Journal of Environmental Research and Public Health in 2021.7 Men aged 37 to 65 who were in the Persian Gulf region in 1990 to 1991 and met Kansas Gulf War illness case criteria were eligible, and the fisetin was sourced from VitaCost and re-encapsulated by a compounding pharmacy.7 The primary outcome was self-reported overall symptom severity on a 0 to 100 scale, with pain and fatigue as secondary outcomes.7 Baseline severity for the fisetin group was 41.9 and the mixed model "did not show a significant main effect for condition", with p = 0.504 and 0.616 for the lower and higher fisetin doses against baseline.7 In the same trial, resveratrol reduced symptom severity significantly more than placebo at both the lower (p = 0.035) and higher (p = 0.004) dosages.7 Fourteen of the 21 participants reported adverse events across the three botanicals, with severity "mild to moderate"; on fisetin, two reported worsening fatigue on 800 mg/day, one each on 200 mg/day and 800 mg/day had "creatinine kinase" elevation as printed in the table, one participant stopped the 800 mg/day dose after one week because of worsening nausea and GERD, one withdrew soon after starting fisetin with a swollen lymph node judged not related to treatment, and the authors state that no statistical analysis of adverse events was done.7 The adverse-event table for the fisetin participants also lists events in the placebo period: worsening fatigue in 1 (against 1 on 200 mg/day and 2 on 800 mg/day) and migraine in 2 (against 1 and 1).7 The authors list limitations including that "Sample sizes were small", that "only men were recruited", that "dosage and duration of treatment were conflated", that carryover was possible, and that "Verification of content can be difficult as sourcing options and purity vary widely".7 The authors add that "study findings are preliminary only and cannot form the basis for treatment recommendations".7 The study was funded by Department of Defense Congressionally Directed Medical Research Programs and National Center for Advancing Translational Sciences awards, and the authors declare no conflict of interest.7

Deeper analysis: the stroke trial with rt-PA (Wang and colleagues, 2019)

Wang and colleagues at Cangzhou Central Hospital, China, reported a double-blind randomised placebo-controlled trial in Clinical and Applied Thrombosis/Hemostasis in 2019.5 Between January 2015 and December 2018, 215 patients were enrolled and 192 were eligible, stratified by onset-to-treatment time into 130 patients at 0 to 3 hours and 62 at 3 to 5 hours.5 Fisetin (100 mg of a Wax Tree derived product) or cellulose placebo was mixed with rt-PA, then given as 100 mg daily for 7 days; the authors chose 100 mg based on a Food and Drug Administration conversion model because this was "the first intervention study in patients with stroke".5 The primary outcome was the NIHSS score and the secondary outcomes were serum MMP-2, MMP-9 and C-reactive protein.5 In the 0 to 3 hour group, day 1 NIHSS scores on fisetin were "statistically indistinguishable" from placebo; in the 3 to 5 hour group, the authors report that fisetin "dramatically improved" outcomes as shown by lower NIHSS scores.5 The scores are given as distributions in figures, and the text read gives no adverse-event counts for fisetin.5 The authors give one limitation: "possible coexistence of infection or inhospital infectious complications was not analyzed".5 The authors declare no conflicts of interest and report no financial support for the research.5

Deeper analysis: the osteoarthritis trial NCT04210986 and COVFIS-HOME

The Steadman Philippon Research Institute entry lists the institute as lead sponsor, a quadruple-masked phase 1/2 design, 34 participants dosed on fisetin and 40 on placebo, and a primary outcome of the number of participants with one or more treatment-emergent adverse events.9 The posted results give 28 of 34 on fisetin and 33 of 40 on placebo with a treatment-emergent adverse event, with an odds ratio of 0.99 (95% CI 0.25 to 4.02); serious events affected 2 of 34 and 2 of 40, and no deaths were reported.9 The participant flow lists 25 of 34 on fisetin and 35 of 40 on placebo as completing the protocol; 9 and 5 did not, because of loss to follow-up (5 and 2), withdrawal by subject (3 and 1), protocol violation (1 and 1) and physician decision (0 and 1).9 The serious events listed for fisetin were a rotator cuff repair and an iatrogenic bladder injury during hip replacement surgery; those for placebo were a lumbar microdiscectomy and surgery for subglottic stenosis.9 A secondary outcome was serum C-reactive protein (unit of measure ug/ml); at month 6 the baseline-adjusted contrast (placebo minus fisetin) was -20.5 (95% CI -37.7 to -3.3) with a Holm-Bonferroni adjusted P value of 0.0829, and the adjusted P value was 0.9728 at day 14, day 45 and month 12.9 The posted results also list secondary outcomes for cartilage oligomeric matrix protein, walking and stair tests, muscle strength, knee pain and function scores, cartilage MRI and conversion to other treatment; the smallest P value listed anywhere in the results was 0.0829.9 The entry lists the principal investigator as a sponsor employee, with Department of Defense and Office of Naval Research collaborators.9 In COVFIS-HOME, the posted results list 26 of 27 analysed participants on fisetin and 22 of 24 on placebo with no activity limitation at 60 days, with two participants in each arm not returning for the 60-day evaluation.10 The adverse event module lists serious events in 0 of 29 on fisetin and 2 of 26 on placebo, other events in 17 of 29 and 16 of 26, and no deaths; the entry posts counts and no p-value or effect estimate for the primary outcome.10 The registry entry names James L. Kirkland as lead sponsor and as Co-Principal Investigator and Regulatory Sponsor, affiliated with Mayo Clinic; Tavenier and colleagues state that patents on senolytic drugs are held by Mayo Clinic, where J.L.K. was employed before a move to Cedars-Sinai.10,2

5

Doses reported in studies and on labels

No drug label for fisetin was returned by a DailyMed search on 16 November 2026, so the table lists doses from studies and registry entries only.

Table 5.1Doses reported in studies and on labels8 rows
Source and settingDose reportedSchedule and routeReference
Krishnakumar 2022, 15 healthy volunteers1000 mg unformulated fisetin; 1000 mg FF-20 delivering 192 mg fisetinSingle oral dose, fasted, 10-day washout1
Wang 2019, stroke with rt-PA100 mgWith rt-PA, then daily for 7 days5
Farsad-Naeimi 2018, colorectal cancer100 mgSeven consecutive weeks, starting one week before chemotherapy6
Hodgin 2021, Gulf War illness200 mg/day, then 800 mg/daySplit between morning and night, 1 month at each dose7
Lee and Burns 2024, healthy adults over 50500 mg dailyOne week per month for six months8
NCT04210986, knee osteoarthritis100 mg capsules, about 20 mg/kg/dayOrally on 2 consecutive days, 28 days off, then 2 more consecutive days9
NCT04771611, COVID-19 outpatientsAbout 20 mg/kg/dayOrally on days 0, 1, 8 and 910
NCT03430037 (AFFIRM), older women20 mg/kg/dayOrally on 2 consecutive days, for 2 consecutive months12

The app's typical dose is 100 to 500 mg/day, and its notes describe a second, pulsed pattern of 1500 mg/day for 2 days monthly; the registry entries above state the pulsed pattern per kilogram of body weight, not as a fixed daily amount.

  • Krishnakumar and colleagues reported two gastrointestinal events, a bloating sensation and a decrease in appetite, after both unformulated fisetin and FF-20 in 15 healthy volunteers.1
  • In the Gulf War illness trial, 14 of 21 participants reported adverse events across three botanicals; on fisetin, worsening fatigue was listed for 1 participant on placebo, 1 on 200 mg/day and 2 on 800 mg/day, and one participant stopped the 800 mg/day dose after one week because of worsening nausea and GERD.7
  • In NCT04210986, 28 of 34 on fisetin and 33 of 40 on placebo had a treatment-emergent adverse event, and serious events affected 2 and 2.9
  • In COVFIS-HOME, other events affected 17 of 29 on fisetin and 16 of 26 on placebo, serious events 0 and 2.10
  • Lee and Burns state that "No adverse effects were noted among the ten subjects".8

The app lists no health markers to monitor for fisetin. Trials measured serum C-reactive protein and cartilage oligomeric matrix protein (osteoarthritis trial), plasma IL-8, IL-10, hs-CRP, MMP-7 and MMP-9 (colorectal cancer trial), and serum MMP-2, MMP-9 and C-reactive protein (stroke trial).9,6,5 COVFIS-HOME excluded patients taking sirolimus, tacrolimus or other mTOR inhibitors, and patients on warfarin.10

8

Regulatory and anti-doping status

No DailyMed drug label for fisetin was returned by a search on 16 November 2026; the search does not cover other regulators or supplement listings. The osteoarthritis registry entry lists fisetin as a dietary supplement intervention and marks the study as FDA regulated drug.9 Fisetin is not named in the text of the World Anti-Doping Agency's 2026 Prohibited List.14 Class S0 covers a pharmacological substance "which is not addressed by any of the subsequent" sections and has "no current approval by any governmental regulatory health" authority for human therapeutic use; the list text does not state whether S0 applies to fisetin.14

The app's 4-hour half-life, 40% bioavailability and 3-hour time to peak were not reproduced by the one human pharmacokinetic study located, which reported shorter half-life and peak times and no absolute bioavailability.1 That study did not measure conjugated metabolites, and it did not compare dosing with and without food.1 The two mouse lifespan reports disagree, and the app's note of a 10% mouse lifespan gain is not printed in either text; the 2024 report describes the earlier result as a median of 27 months in controls and 30 months with fisetin.3,4 Tavenier and colleagues, who include Kirkland and Tchkonia, write that "further studies are needed to establish the safety, pharmacokinetics, and efficacy of fisetin as a senotherapeutic".2 The query "fisetin randomized placebo-controlled trial humans" returned 6 PubMed results and was not aimed at senescent-cell outcomes, so whether a report of such an outcome exists is not determined; the registry entry read for a senescence-index trial (NCT07918261) lists no posted results.13

What is the half-life of fisetin?

In a crossover study of 15 healthy volunteers, plasma fisetin had a half-life of 1.14 hours unformulated and 1.51 hours as a formulated product, and the app lists 4 hours.1 Yousefzadeh and colleagues cite rapid and terminal half-lives of 0.09 and 3.1 hours in the discussion of their mouse experiments, in a sentence that does not name the species.3

How long does fisetin take to reach its peak level?

In the same crossover study the mean time to maximum plasma concentration was 0.88 hours for unformulated fisetin and 1.24 hours for the formulated product, and the app lists about 3 hours.1

What is the bioavailability of fisetin?

The 2022 crossover study reports no absolute bioavailability percentage, and the app lists 40%.1 Its authors write that the study "demonstrated the poor bioavailability of fisetin in human subjects", and plasma fisetin from the formulated product had an AUC 26.9-fold greater than from unformulated fisetin.1

Is fisetin approved by the FDA?

No DailyMed drug label for fisetin was returned by a search on 16 November 2026. The osteoarthritis registry entry lists the intervention as a dietary supplement.9

Is fisetin banned by WADA?

Fisetin is not named in the text of the 2026 WADA Prohibited List.14 Class S0 covers pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use, and the list text does not state whether it applies to fisetin.14

Does fisetin extend lifespan in mice?

One study (n = 8–9 mice per group for lifespan) reported that fisetin extended median and maximum lifespan in aged wild-type mice, and another, which states it used 30 × larger numbers of mice, reported no significant lifespan increase in UM-HET3 mice at the doses and schedules tested.3,4

Has fisetin been tested in people?

Fisetin has been given to people in a pharmacokinetic study of 15 healthy volunteers and in trials in colorectal cancer (37 patients), stroke (192 patients), Gulf War illness (21 veterans across three botanicals, 11 of them with fisetin results), knee osteoarthritis (34 on fisetin and 40 on placebo) and COVID-19 outpatients (29 on fisetin and 26 on placebo).1,6,5,7,9,10 The Gulf War illness trial reported that fisetin did not reduce symptom severity at 200 or 800 mg/day (p = 0.504 and 0.616).7

What side effects have been reported in fisetin trials?

Two gastrointestinal events, bloating and decreased appetite, were reported in the 15-volunteer pharmacokinetic study; in the Gulf War illness trial two veterans reported worsening fatigue on 800 mg/day and one stopped the 800 mg/day dose after one week because of worsening nausea and GERD.1,7 In the osteoarthritis registry results, 28 of 34 on fisetin and 33 of 40 on placebo had a treatment-emergent adverse event.9 Serious events affected 2 of 34 on fisetin and 2 of 40 on placebo in that trial, and 0 of 29 on fisetin and 2 of 26 on placebo in COVFIS-HOME.9,10

12

References

  1. Krishnakumar IM, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci 2022. PMID 36304817
  2. Tavenier J, et al. Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mech Ageing Dev 2024. PMID 39384074
  3. Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 2018. PMID 30279143
  4. Harrison DE, et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. GeroScience 2024. PMID 38041783
  5. Wang L, et al. Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Clin Appl Thromb Hemost 2019. PMID 31434498
  6. Farsad-Naeimi A, et al. Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food Funct 2018. PMID 29541713
  7. Hodgin KS, et al. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea). Int J Environ Res Public Health 2021. PMID 33802381
  8. Lee E, Burns M. The Effects of Fisetin on Reducing Biological Aging: A Pilot Study. Altern Ther Health Med 2024. PMID 39269340
  9. Steadman Philippon Research Institute. Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial. ClinicalTrials.gov NCT04210986. NCT04210986
  10. Kirkland JL. COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications. ClinicalTrials.gov NCT04771611. NCT04771611
  11. Mayo Clinic. COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation. ClinicalTrials.gov NCT04476953. NCT04476953
  12. Mayo Clinic. Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (AFFIRM). ClinicalTrials.gov NCT03430037. NCT03430037
  13. Steadman Philippon Research Institute. Evaluation of Fisetin to Reduce Systemic Senescence. ClinicalTrials.gov NCT07918261. NCT07918261
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list